Optimal fixed low-dose combination of glibenclamide and metformin

• Krivosheeva A.A.

AbstractDiabetes mellitus type 2 (T2DM) is a global problem of world health. Clinical studies show that early glucose-lowering therapy reduces the risk of complications, and recommend the use of lifestyle changes along with the initial combination therapy. Management of T2DM can be can be facilitated by using combinations of low doses of drugs in a single tablet, allowing patients to take fewer tablets per day, which can lead to improved patient compliance, and also provide good efficacy with low side effects, as demonstrated when taking Glibenclamide and Metformin. Oral combination therapy, which takes into accountthe two major pathogenetic mechanisms, insulin resistance and beta-cell dysfunction, is a proven means of improving glycemic control. This therapy is associated with significantly improved control of glycemia at lower doses of Metformin and Glibenclamide, a low risk of hypoglycemia and a lack of weight gain.

Keywords:Glibenclamide, Metformin, fixed-dose combination of low-dose glucose-lowering drugs, diabetes mellitus type 2

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)